Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey

BEKSAÇ M., CENGİZ SEVAL G., PAYDAŞ S., Tuglular T. F., ARSLAN Ö., GÖKER H., ...More

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.19, no.10, 2019 (SCI-Expanded, Scopus)

• Publication Type: Article / Abstract
• Volume: 19 Issue: 10
• Publication Date: 2019
• Doi Number: 10.1016/j.clml.2019.09.402
• Journal Name: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Keywords: elotuzumab, immunomodulatory drugs, Multiple myeloma
• Ankara University Affiliated: Yes